Medical network - on April 25, recently, the ministry of human resources and social security (hereinafter referred to as the club's department) identified in 2017 national basic medical insurance, inductrial injury insurance and maternity insurance drug catalogue negotiations range of 44 species list, involving 32 enterprises, including: 19 domestic varieties, involving 18 Chinese companies; 25 imported varieties, involving 14 foreign-capital enterprise. In the domestic varieties, involving 10 a-share listed companies of 11 varieties, some products for the company's main products. 

 

Cut prices, experts say, will become an important factor can eventually enter medical insurance directory. After entering medical insurance directory, whether to reduce the price "in" the market, also to a certain extent, depend on the condition of the competing goods into the medical insurance directory. 

 

1 varieties give up health care medicine 

 

In February 2017, the people club department website released a new version of the national basic medical insurance, inductrial injury insurance and maternity insurance drug catalogue (2017 edition), 45 to negotiate new drugs. , director-general of the department of the ministry of social health insurance Chen Jinfu has said that given the part of the drug has a high clinical value, but the price is more expensive, according to the current price included in the catalog can bring high pressure, medical insurance fund experts review identified 45 to negotiate drug, the next step will be negotiated lower the price and then into the appropriate directory. After confirm whether relevant enterprises have negotiations intention, publish to the society plans to negotiate drug list and according to related procedure organization negotiations, agreed varieties should be brought into the scope of medical insurance fund pays. 

 

People club department last week released the final list, make sure the 44 drug varieties in 2017 national basic medical insurance, inductrial injury insurance and maternity insurance drug catalogue negotiations. That is to say, there are a variety abandoned drug negotiations. 

 

The Beijing news reporter query, statistics, found that 44 drugs including 19 kinds of domestic drugs, 25 kinds of imported drugs. Among them, the chemicals occupy half, a total of 22 varieties, biological products to 14, proprietary Chinese medicine eight. 

 

The personage inside course of study says, the varieties of going into the range of embodies the six major characteristics: going into the directory just need most of the drugs for patients, clinical value is high, the price is higher, the sole drug domestic substitution, support for domestic innovation medicine and traditional Chinese medicine (TCM), cancer and cardiovascular medicines are key areas. 

 

Anti-tumor, regulating immune drugs into a hero 

 

It is worth noting that, in accordance with the drug to treat disease, negotiations directory covers the tumor, cardiovascular disease, blood and hematopoietic system etc. 10 fields. Varieties of anti-tumor and immune modulators of 22 number, become absolutely "leading role". 

 

By going into the catalogue of cetuximab injection as an example, this is a highly active IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), can reduce the invasion of tumor cells to normal tissue and the speed of the cancer cells spread to new areas, has more than 90 countries around the world get used in the treatment of colorectal cancer and head and neck squamous cell carcinoma of the marketing authorisation. As of April 2017, our country already has 11 cities include cetuximab in health care. 

 

Beijing cancer hospital digestive tumors of doctor of medical director li yan said in an interview with Beijing news reporter, can is a lot of coverage, including colorectal cancer patients, cancer patients in choosing drugs when the first consideration, rather than the curative effect. "After the medicine into the medical insurance directory, for cancer patients, the extension of treatment cycle is the most obvious change, for the situation and survival after tumor patients is important. Some drugs, the sooner you use, can better control the tumor, the patient's quality of life will also improve. As the using time delay, drug potency than decreases." 

 

10 listed companies directory products for negotiation 

 

In his nomination of 19 kinds of Chinese medicine, involving 10 a-share listed companies of 11 kinds of products, including both, red sun pharmaceutical co., billion sails medicine, tasly, kang edge pharmaceutical, letter litai, yasuhiro miyata pharmaceutical, hengrui pharmaceutical medicine, Tibetan medicine, Shanghai. Shortlisted for the medicine, with some companies, its main products, including, compaq heap eye ophthalmic injection (mu) is yasuhiro miyata pharmaceutical industry after 10 years of independent research and development, with independent intellectual property rights of national original type of biological medicines. The company reported in 2016, lang mu revenue of 476 million yuan, up 78% year on year, become the company's fastest-growing item. In addition, the shortlist for talks after injection for reasons of gas pulse (lyophilization) is one of the core product of tasly. 

 

Can enter the medical insurance directory, the pharmaceutical producing enterprises and has important influence on capital market. Released the new medical insurance directory this year, for example, the directory released in the afternoon, A shares drug sector ahead of explosion, the pharmaceutical industry, sunflower, pharmaceutical, and other listed companies appeared to harden. Medical insurance directory of toxic heat in 2010, the drug for kang edge pharmaceutical industry's main variety of product lines, the representative of the respiratory system. Before entering the medical insurance directory, the drug sales income is 198 million yuan, in 2009 to 2016, the company operating income of more than 3 billion, including toxic heat ning injection operating income for more than 10%. 

 

Tibet Tibet di kang pharmaceutical co., LTD. (pharmaceutical) released announcement, through negotiations, such as the late was placed on the medical insurance to pay limits, will be conducive to the company the sale of drugs, short-term will not have a significant impact on company's performance. 

 

Reduction will become important factor into the directory 

 

Third-party medical service system MaiSiKang lai founder Shi Lichen pointed out that "directory access to health care negotiations, waiting to negotiate results, of course." Reduction will be the drug will ultimately important factor into the medical insurance directory, "because the product quality and technology level, there is already no obvious differences." 

 

According to the results of the 2016 national first batch of drug price negotiations in "down" to negotiate drug prices are encountered, glaxosmithkline first-line treatment chronic hepatitis b drug tenofovir ester (viread), zhejiang beida non-small cell lung cancer targeted therapy drugs for ek's (kaimei na) and the treatment of astrazeneca (Yi Rui sand) of three kinds of drugs price decline reached 67%, 67% and 67% respectively. 

 

"If the end into the medical insurance directory, whether to reduce the price in the market, we have to look at competing goods into the medical insurance directory, health care coverage is wider, to reduce the price in the market, the harder it becomes." In addition, some drug sales have reached a certain level, "even into the medical insurance directory, sales growth is limited, double double long hard to happen." Shi Lichen said, in the field of the same disease, the more involved in the talks and drug kinds, can release the sales bonus. 

 

Health-care negotiation process 

 

First confirm whether related enterprise has the intention to negotiate, and then publish to the society plans to negotiate drug list and according to related procedure organization negotiations, agreement of varieties can be incorporated into the scope of medical insurance fund pays.